Xilio Therapeutics announces offering of warrants, no amount given

Xilio Therapeutics (XLO) announced that it is commencing an underwritten public offering of pre-funded warrants to purchase shares of common stock accompanied by Series A warrants to purchase shares of common stock, Series B warrants to purchase shares of common stock, and Series C warrants to purchase shares of common stock. All of the securities to be sold in the proposed offering will be offered by Xilio. Leerink Partners is acting as the sole bookrunner for the offering.